Précisez une action ou une cryptomonnaie dans la barre de recherche pour obtenir un récapitulatif
AnGes Inc
4563AnGes, Inc., a biopharmaceutical company, engages in the research and development of gene-based medical products. Its lead product is Hepatocyte Growth Factor (HGF) Plasmid, a gene therapy for the treatment of ischemic diseases. The company is also developing NF-kB Decoy Oligonucleotide, a nucleic acid medicine that suppresses inflammation for diseases, including low back pain; drugs for treating atopic dermatitis and asthma; medical devices for the prevention of vascular medicine; cervical intraepithelial neoplasia therapeutic vaccines for cervical cancer; and DNA vaccines for high blood pressure through collaborative research agreement with Osaka University. The company was formerly known as AnGes MG, Inc. and changed its name to AnGes, Inc. in July 2017. AnGes, Inc. was incorporated in 1999 and is headquartered in Ibaraki, Japan. Address: Saito Bio-Incubator, Ibaraki, Japan, 567-0085
Analytics
Objectif de Cours de WallStreet
94 471.76 JPYRatio C/B
–Rendement du dividende
–Année actuelle
L'année dernière
Trimestre en cours
Le dernier trimestre
Année actuelle
L'année dernière
Trimestre en cours
Le dernier trimestre
Chiffres clés 4563
Analyse des dividendes 4563
Croissance des dividendes sur 5 ans
–Croissance continue
–Ratio de distribution Moyenne sur 5 ans
–Historique des dividendes 4563
Valorisation des titres 4563
financières 4563
Résultats | 2019 | Dynamique |